## "Express Mail Certificate JC12 Rec'd PCT/PTC 30 Express Mail Mailing Label Number EV710806492US

Date of Deposit: 30 September 2005

Attorney Docket No. PB60196

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Nicola M. Aston

30 September 2005

Int'l Serial No.: PCT/EP2004/003773

Group Art Unit No.: unknown

Filed:

Herewith

Examiner:

unknown

For:

Biphenylcarboxylic Amide Derivatives As P38 Kinase Inhibitors

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### FILING OF AN INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R.§1.97(b)

The attached list of citations on PTO Form 1449 is being submitted under the provisions of 37 CFR §1.56 and §1.97 for consideration by the United States Patent and Trademark Office, prior to the granting of this patent. Their inclusion herein should not, however, be construed as an admission that any particular cited document is effective prior art or that it discloses or renders obvious any aspect of the claimed invention. A copy of each cited document is enclosed, except for the US patents and publications. This statement is being filed under the provisions of 37 C.F.R. §1.97(b). No fee is required.

In order to simplify the number of references and reduce duplicative submissions listed in this Information Disclosure Statement, Applicants have prepared a summary of corresponding US Patents to their respective WIPO Publications. It should be noted that Applicants only list a representative number of the corresponding US Patents and Publications on the PTO 1449 form and do not assert that this is a full and complete listing thereof. As the US patents are no longer required to be submitted, copies of these do not accompany this response. Should the Examiner wish copies of these Patents or Publications, please advise the undersigned at the number indicated below.

	$^{\circ}$	
-	Z	-

	Corresponding
Foreign Patent	US Patent
DE 10063008	US 2004/038858
	US 2005/137230
DE 10110749	US 2004/176446
DE 19817461	US 6,436,925
EP 0 849 256	US 6,174,887
	US 6,420,561
WO 00/41698	US 2001/011135
	US 2001/011136
	US 2001/016659
	US 2001/027202
	US 2001/034447
	US 2002/042517
	US 2002/065296
	US 2002/137774
	US 2002/165394
	US 2003/105091
	US 2003/139605
	US 2003/181442
WO 99/59959	US 6,579,872
	US 2003/212068
WO 00/50000	TIC ( 400 166
WO 00/52008	US 6,498,166
WO 98/56377	US 6,774,127
	US 2002/156104
NO 01/14275	US 2003/153569
WO 01/14375	US 6,855,719
EP 0 849 256	US 6,174,887
	US 6,420,531
WO 99/59959	US 6,579,872
	US 2003/212068
·	

Corresponding
US Patent
US 5,534,518
US 5,616,718
US 5,874,579
US 5,858,995
US 6,638,980
US 6,509,363
US 2002/016471
US 6,130,235
US 6,340,685
US 6,448,257
US 6,589,954
US 6,864,260
US 6,869209
US 2003/073699
US 2003/144520
US 2003/158417
US 2003/162970
US 2003/195355
US 6,451,792
US 6,831,097
US 6,861,429
US 2003/008872
US 2003/040517
US 2005/113377
US 6,509,361
US 5,521,213
US 6,329,421
, ,
US 6,821,965
US 2005/038081
US 6,696,464
US 2003/096838

- 3 -

The Examiners attention is also drawn to the entry of the copending PCT applications PCT/EP2004/003769 published as WO 04/089875 and PCT/EP2004/003774 published as WO 04/089874, as well as those shown below, in tabular form.

_	
	Corresponding
Foreign Patent	US Patent
WO 03/032980	US 2005/0038014
	USSN 10/492,699
WO 03/03298	US 2004/0266839
	USSN 10/492,713
WO 03/033457	US 2004/0249161
	USSN 10/492,715
WO 03/033483	US 2005/0020540
	USSN 10/492,697
WO 03/068747	USSN 10/503,908

Foreign Patent	Corresponding US Patent
WO 03/033482	US 2005/0065196
	USSN 10/492,711
WO 03/032987	US 2005/0090491
	USSN 10/492,497
WO 03/032971	US 2004/0242868
	USSN 10/492,605
WO 03/032972	US 2004/0237012
	USSN 10/492,698
WO 03/032970	USSN 10/492,714

Should the Examiner have any questions or wish to discuss any aspect of this case, the Examiner is encouraged to call the undersigned at the number below. If any additional fees or charges are required by this paper the Commissioner is hereby authorized to charge Deposit account 19-2570 accordingly.

Respectfully submitted,

Attorney for Applicants

Registration No. 33,680

GLAXOSMITHKLINE Corporate Intellectual Property - UW2220 P.O. Box 1539 King of Prussia, PA 19406-0939 Phone (610) 270-5022 Facsimile (610) 270-5090 Sheet 1 of 4.

Form PTO-1449	U.S. Department of Commerc
	Patent and Trademark Office

ATTY. DOCKET NO. PB60196

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

APPLICANT Aston, et al.

FILING DATE

Herewith

GROUP Unknown

(Use several sheets if necessary)

			U.S. PATENT DOCUMENTS		T	
Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	2001/011135	2 Aug 01	Reidl, et al.			
	2004/0242868	2 Dec 04	Angell, et al.			
	2004/0249161	9 Dec 04	Angell, et al.			
	2004/0266839	30 Dec 04	Angell, et al.			
	2004/0267012	30 Dec 04	Angell, et al			
	2004/038858	26 Feb 04	Dorsch, et al.			
	2004/176446	9 Sep 04	Alonso-Alija, et al.	<u> </u>		
	2005/0020540	27 Jan 05	Angell, et al.			
	2005/0020590	27 Jan 05	Lang, et al.			
	2005/0038014	17 Feb 05	Angell, et al.			
	2005/0065195	24 Mar 05	Angell, et al.			- 1 - 2 - 1 - 1 - 1 - 1
	2005/0090491	28 Apr 05	Angell, et al.			
	4,200,750	29 Apr 80	Warner, et al.			
	5,236,934	17 Aug 93	VanAtten			
	5,246,943	21 Sept 93	Blankley, et al.			
	5,521,213	28 May 96	Prasit, et al.			
	5,534,518	9 Jul 96	Henrie, et al.			1.505
	5,658,903	19 Aug 97	Adams, et al.			
	5,858,995	12 Jan 99	Kawai, et al.			
	5,932,576	03 Aug 99	Anantanarayan, et al.			
	5,945,418	31 Aug 99	Bemis, et al.			
	5,977,103	02 Nov 99	Adams, et al.			
	6,087,496	11 Jul 00	Anantanarayan, et al.			
	6,130,235	10 Oct 00	Mavunkel, et al.			
	6,130,235	10 Oct 00	Mavunkel, et al.			
	6,147,080	14 Nov 00	Bemis, et al.			
	6,174,887	16 Jan 01	Haruta, et al.			
	6,174,887	16 Jan 01	Harute, et al.			
	6,251,914	26 Jun 01	Adams, et al.			
	6,277,989	21 Aug 01	Chakravarty, et al.			
	6,436,925	20 Aug 02	Lubisch, et al.			

6,451,794	17 Sep 02	Beswick, et al.	
6,498,166	24 Dec 02	Campbell, et al.	
6,509,361	28 May 03	Weier, et al.	
6,509,363	21 Jan 03	Salituro, et al.	
6,579,872	17 Jun 03	Brown, et al.	
6,579,872	17 Jun 03	Brown, et al.	
 6,638,980	28 Oct 03	Su, et al.	
6,696,464	24 Feb 04	McClure, et al.	
6,774,127	10 Aug 04	Adams, et al.	
6,821,965	23 Nov 04	Brown, et al.	
6,855,719	15 Feb 05	Thomas, et al.	

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Trans	
						Yes	No
	0 346 841	5 June 03	EP				
	0 430 033	8 April 04	EP				
	0 533 266	14 Sep 92	EP		Ž /		
	0 533 268	14 Sep 92	EP				
	2 273 930	17 Dec 93	GB				_
	2 276 161	17 Mar 93	GB		ļ <u>.</u>		
	2 276 162	17 Mar 93	GB				
	2 295 387	29 May 96	GB				
	WO 00/12074	9 Mar 00	WIPO				
	WO 00/12497	9 Mar 00	WIPO				
	WO 00/26216	11 May 00	WIPO				
	WO 00/56738	28 Sep 00	WIPO				
_	WO 00/71493	30 Nov 00	WIPO				
	WO 00/71509	30 Nov 00	WIPO			_	
	WO 00/71510	3 Nov 00	WIPO				<u></u>
	WO 00/71511	30 Nov 00	WIPO		<u> </u>		
	WO 01/27089	19 Apr 01	WIPO				l
	WO 01/34605	17 May 01	WIPO				
	WO 01/70695	27 Sep 01	WIPO				
	WO 01/87875	22 Nov 01	WIPO				

Sheet 3 of 4. SERIAL NO. 100 / 1 501 ATTY. DOCKET NO. Form PTO-1449 U.S. Department of Commerce Patent and Trademark Office PB60196 APPLICANT INFORMATION DISCLOSURE STATEMENT Aston, et al. BY APPLICANT **GROUP** FILING DATE Unknown (Use several sheets if necessary) Herewith

	WO 02/40486	23 May 02	WIPO
	WO 03/032970	24 Apr 03	WIPO
	WO 03/068747	21 Aug 03	WIPO
	WO 03/093248	13 Nov 03	WIPO
	WO 04/010995	05 Feb 04	WIPO
-	WO 04/089874	21 Oct 04	WIPO
	WO 04/089875	21 Oct 04	WIPO
	WO 05/014550	17 Feb 05	WIPO
· ·	WO 05/061465	07 Jul 05	WIPO
	WO 94/15920	21 Jul 94	WIPO
	WO 95/06636	09 Mar 95	WIPO
	WO 95/06644	09 Mar 95	WIPO
	WO 95/11243	27 Apr 95	WIPO
-	WO 95/15954	15 Jun 95	WIPO
	WO 95/17401	29 Jun 95	WIPO
	WO 95/29907	9 Nov 95	WIPO
	WO 95/30675	16 Nov 95	WIPO
	WO 96/31508	10 Oct 96	WIPO
	WO 96/31509	10 Oct 96	WIPO
	WO 97/03034	30 Jan 97	WIPO
	WO 99/32463	1 Jul 99	WIPO

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Boehm et al., Expert Opinion of Therapeutic Patents, Vol. 10 (1) pgs 25-37 (2000)
Boehm, et al, Journal of Medicinal Chemistry, Vol 39(20) pgs 3929-3937 (1996)
Ceccarelli et al., European Journal of Medicinal Chemistry, Vol. 33 (12) pgs 943-955 (1998)
Gabriele et al., European Journal of Organic Chemistry, Vol. 2001 (24) pgs 4607-4613 (2001)
Han et al., Biohemica et Biophysica Acta - Molecular Cell Research, Vol. 1265 (2-3) pgs 224-227 (1995
Hanson, Expert Opinion on Therapeutic Patents, Vol. 7(7) pgs 729-733 (1997)
Henry et al., Drugs of the Future, Vol. 24 (12) pgs 1345-1354 (1999)
Jiang et al, Journal of Biological Chemistry, Vol 271 (30) pgs 17920-17926 (1996)

# JC12 Rec'd PCT/PTC 3 0 SEP 2005

Sheet <u>4</u> of <u>4</u> .				
Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	PB60196	10 5 1 5 0 1	
INFORMATION	DISCLOSURE STATEMENT	APPLICANT		
BY APPLICANT		Aston, et al.		
		FILING DATE	GROUP	
(Use seve	eral sheets if necessary)	Herewith	Unknown	

Li et al., Biochemical and Biophysical Research Communications, Vol. 228 (2) pgs334-340 (1996)
Liebeskind et al., Organic Letters, Vol. 4 (6) pgs 979-981 (2002)
Moreland et al., Annals of Internal Medicine, Vol 130 (6) pgs 478-486 (1999)
Murali Dhar et al., Bioorganic and Medicinal Chemistry Letters, Vol. 12 (21) pgs 3125-3128 (2002)
Rankin et al., British Journal of Rheumatology, Vol. 34 pgs334-342 (1995)
Salituro et al., Current Medicinal Chemistry, Vol. 6 pgs 807-823 (1999)
Wang et al., Journal of Biological Chemistry, Vol. 272 (38) pgs 23668-23674 (1997)
DATE CONSIDERED

•EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copyof this form with next communication to applicant.